A Case of Metastatic Adamantinoma That Responded Well to Sunitinib.
| Autor: | Liman AD; Hematology and Oncology, VA Pittsburgh Healthcare System, University of Pittsburgh School of Medicine, Pittsburgh, PA 15240, USA., Liman AK; Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh School of Medicine, Pittsburgh, PA 15240, USA., Shields J; Pharmacy, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA., Englert B; Hematology and Oncology, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA., Shah R; Radiology, VA Pittsburgh Healthcare System, University of Pittsburgh School of Medicine, Pittsburgh, PA 15240, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Case reports in oncological medicine [Case Rep Oncol Med] 2016; Vol. 2016, pp. 5982313. Date of Electronic Publication: 2016 Aug 17. |
| DOI: | 10.1155/2016/5982313 |
| Abstrakt: | Adamantinoma is a rare low-grade malignant bone tumor of epithelial origin. Metastatic adamantinoma has been reported to be resistant to chemotherapy. We report a case of metastatic adamantinoma to the lung, 10 years after the initial diagnosis of tibial mass. The patient received radiation therapy to the lung with partial response. A surveillance PET scan revealed progression of the lung mass and biopsy confirmed to be progressive residual metastatic adamantinoma. He received carboplatin and etoposide for 7 months and achieved a partial response. Four months later, PET scan showed disease progression. We started him on sunitinib, a multikinase inhibitor. He achieved a good partial response for 3 years. He died due to pneumonia at the age of 72. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|